Semaglutide and tirzepatide are the two GLP-1 medications most relevant to weight management. Both are weekly injections used in physician-supervised protocols. Tirzepatide acts on two receptors (GIP and GLP-1) and tends to produce a stronger appetite-modulation profile than semaglutide, which acts on GLP-1 alone. Whether either is appropriate for you is determined by a U.S. licensed physician.
The hard parts: nausea in the first 2-4 weeks, the risk of losing significant muscle mass alongside fat, the need to actually keep eating protein and training, and the question of what happens when you stop. None of these are reasons to avoid the medications. They are reasons to use them with a real protocol around them.
What this guide covers
How GLP-1 medications work
GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. It does three useful things: it signals satiety to your brain, it slows gastric emptying so food sits in your stomach longer, and it improves insulin sensitivity. GLP-1 receptor agonist medications are synthetic analogs of this hormone, dosed weekly, that hold those signals at therapeutic levels around the clock (Drucker, Cell Metab 2018).
Semaglutide activates one receptor (GLP-1). Tirzepatide activates two (GLP-1 and GIP, glucose-dependent insulinotropic polypeptide). That second receptor is why tirzepatide produces meaningfully more weight loss on average — GIP signaling amplifies appetite suppression and improves how your body uses fat for fuel.
If you want the deeper mechanism, see GLP-1s in the brain for how appetite is actually rewired, and food noise for the subjective experience commonly described within the first month.
Semaglutide vs tirzepatide, head to head
The simplest version of the choice: tirzepatide is the stronger weight-loss molecule; semaglutide has the longer track record and is cheaper. Both are weekly subcutaneous injections.
| Marker | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 agonist | Dual GIP / GLP-1 agonist |
| OPTML price (compounded) | $249/mo | $349/mo |
Choosing between the two is a conversation to have with a U.S. licensed physician based on your history, tolerance, and goals.
Who GLP-1 medications are for
The long-standing clinical eligibility framework for GLP-1 weight-management protocols is BMI 30+ (obesity), or BMI 27+ (overweight) with at least one weight-related condition (high blood pressure, type 2 diabetes, dyslipidemia, sleep apnea, etc.). Whether you are a candidate is determined by a U.S. licensed physician.
That said, the "right candidate" question is rarely about BMI alone. It's about whether weight loss is a leverage point on your specific health trajectory. Some realistic profiles where GLP-1s tend to be the right tool:
- The 30+ lb weight-to-lose adult who has lost and regained weight repeatedly. GLP-1s solve for the satiety setpoint that diet alone can't.
- The metabolically dysfunctional but lean-ish adult. Visceral fat, insulin resistance, fatty liver — GLP-1s improve all three independent of total weight loss.
- The already-fit optimizer who's stalled. Microdosing (lower doses, see microdose GLP-1) gets some of the metabolic upside without the dramatic appetite suppression.
Articles on candidacy: how GLP-1s work · food noise, explained · bloodwork first.
What to expect, month by month
The trajectory is reasonably predictable. The pattern below is what physicians in our network see most often; individual variation is wide.
Month 1
You will start low and stay there for a while, for one reason: tolerance. Expect mild nausea in the first 24-72 hours after each dose, particularly weeks 1-3. Hunger signal noticeably dampens by week 2. Weight loss in month 1 is typically minimal. The point of month 1 is not weight loss — it's confirming tolerance and titrating up.
Months 2-3
Doses titrate up monthly. Appetite suppression is now substantial — many describe being "uninterested" in food rather than feeling forced to restrict. Individual results vary. This is the easiest stretch.
Months 4-9
Steady progression. Weight loss varies by individual, dose, and adherence. Plateaus are common around month 4-5 and again around month 7-8 — usually resolved by another titration step or a protocol tweak.
Months 10-18
Weight loss continues at a slower rate. By month 12-15, weight loss typically approaches a plateau. This is when the muscle-preservation conversation becomes critical (see next section).
Deep dives on the trajectory: weight-loss plateaus · when a GLP-1 stops working · what happens when you stop.
Side effects, what's real and what's overblown
GLP-1 side effects fall into three categories: the predictable ones (manageable), the rare-but-real ones (worth knowing about), and the manufactured ones (overblown in media).
Predictable: GI tolerance
Nausea, constipation, occasional reflux. Almost always worst in the first 1-3 weeks of any new dose. Resolved by slower titration, smaller meals, and hydration. See the side-effect guide for tactical management.
Real but rare: pancreatitis, gallbladder, gastroparesis
These exist but are uncommon and signal-flagged (Sodhi et al., JAMA 2023). Pancreatitis: ~0.2% incidence in trials, less than the background rate in patients with obesity. Gallbladder disease: increased modestly (He et al., JAMA Intern Med 2022), mostly during rapid weight loss (true of any rapid weight loss). Gastroparesis: very rare; nearly always reverses on discontinuation.
Overblown: facial volume changes, hair thinning, alcohol metabolism
Facial volume changes during fast weight loss are just fat loss showing up in the face. Not a unique pharmacologic effect. Hair thinning during significant weight loss happens whether you're on a GLP-1 or not — it's a telogen-effluvium response to caloric deficit. Alcohol changes are real but mild.
Muscle preservation, the biggest miss
A large share of the weight lost in any rapid calorie deficit, a GLP-1 included, is lean mass — muscle, organ tissue, water (Cava et al., Adv Nutr 2017). Resistance training and adequate protein are what shift that split; energy restriction on its own does not (Weinheimer et al., Nutr Rev 2010). That's the number that almost nobody talks about and that quietly determines whether your GLP-1 outcome is a win or a setback in five years.
Muscle mass drives resting metabolic rate, insulin sensitivity, glucose disposal, fall risk, and all-cause mortality. Losing 30 lb of which 12 lb was muscle leaves you with a lower metabolic floor and lower long-term healthspan than losing 30 lb of which 5 lb was muscle. Both look identical on the scale.
The protective protocol is unambiguous:
- Protein: 1.0-1.2 g per pound of goal body weight, daily. Most patients fall to ~50-60 g/day on a GLP-1 unless they actively track. Plan it.
- Resistance training: 3-4 sessions weekly, progressive overload on compound lifts. Cardio is fine but does not preserve muscle.
- Adequate calories: Don't compound an aggressive deficit on top of GLP-1-induced appetite suppression. A 500 kcal/day deficit is plenty.
Articles: the muscle-preservation playbook · training on a GLP-1 · protein on a GLP-1.
Microdosing GLP-1s
Microdose GLP-1 protocols use 25-50% of the standard maintenance dose. The use case isn't weight loss — it's metabolic and anti-inflammatory optimization for people who are already lean or near-lean and want the cardiometabolic upside without dramatic appetite suppression.
Microdosing maps to a different patient: the already-fit optimizer, the post-significant-weight-loss maintainer, the metabolically dysfunctional but BMI-normal adult. See our microdose page for the protocol detail, and for the conceptual frame.
What happens when you stop
Withdrawal of GLP-1 receptor agonist therapy is associated with regain of a substantial fraction of lost weight over the subsequent year in the published literature on semaglutide discontinuation. Weight regain on GLP-1 discontinuation is not a moral failure — it's the predictable consequence of removing a satiety signal you've been holding artificially.
The maintenance answer is one of three:
- Stay on a maintenance dose indefinitely. Most realistic for patients with significant weight to lose. Semaglutide and tirzepatide are safe long-term per current evidence.
- Step down to microdose. A lower dose holds enough satiety signal to prevent the rebound without full appetite suppression.
- Off-cycle with a serious lifestyle backbone. Possible if the lean mass was preserved, the training pattern is established, and the patient is comfortable with some weight regain.
See what happens when you stop · maintenance after weight loss · holding on to the result.
Frequently asked questions
Will I have to stay on a GLP-1 forever?
Not necessarily, but probably for longer than you initially think. People who maintain results generally either stay on maintenance dosing, step down to a microdose, or transition off with a strong lifestyle backbone. The "weeks-of-treatment" mental model from antibiotics doesn't apply.
Is one safer than the other?
Both have well-characterized safety profiles. Tirzepatide produces slightly more nausea on average; semaglutide has the longer safety record.
Can I drink alcohol?
Yes, in moderation. Tolerance is often reduced, and less is typically wanted. See GLP-1s and alcohol.
Will I lose muscle?
Some, yes, unless you train and eat protein. See the muscle preservation section.
Can I exercise normally?
Yes. Lifting is encouraged; cardio is fine. Mild fatigue can occur in week 1 of a new dose and typically resolves.
